Browse > Article
http://dx.doi.org/10.5009/gnl17462

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease  

Park, Jihye (Department of Internal Medicine, Yonsei University College of Medicine)
Cheon, Jae Hee (Department of Internal Medicine, Yonsei University College of Medicine)
Publication Information
Gut and Liver / v.12, no.6, 2018 , pp. 623-632 More about this Journal
Abstract
Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor-${\alpha}$, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet's disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor-${\alpha}$ for the treatment of intestinal Behçet's disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet's disease. This review also discusses safety issues associated with anti-tumor necrosis factor-${\alpha}$, including vulnerability to infections and malignancy.
Keywords
Behcet syndrome; Intestinal Behcet's disease; Anti-tumor necrosis factor alpha; Infliximab; Adalimumab;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ideguchi H, Suda A, Takeno M, et al. Gastrointestinal manifestations of Behcet's disease in Japan: a study of 43 patients. Rheumatol Int 2014;34:851-856.   DOI
2 Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun 2015;62:67-74.   DOI
3 Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863.   DOI
4 Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet's disease treated with infliximab. Dig Dis Sci 2017;62:441-447.   DOI
5 Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-728.   DOI
6 Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46:118-121.   DOI
7 Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-27.   DOI
8 Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behcet's disease: report of a case. Dis Colon Rectum 2007;50:672-676.   DOI
9 Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behcet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008;46:212-215.   DOI
10 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-881.   DOI
11 Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268-274.   DOI
12 Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014;8:31-44.   DOI
13 Stubiger N. Behcet's disease. Epidemiology, clinical manifestations, immunology and therapy. Ophthalmologe 2012;109:529-530.   DOI
14 Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis 2017;11:954-962.   DOI
15 Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behcet's disease. Clin J Gastroenterol 2014;7:205-212.   DOI
16 James DG. Behcet's syndrome. N Engl J Med 1979;301:431-432.   DOI
17 Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximaband immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-1063.   DOI
18 Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol 2015;50:312-320.   DOI
19 Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis 2014;8:282-287.   DOI
20 Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999;341:1284-1291.   DOI
21 Nakata K, Murakami T, Hashi N, Tsutsumi S. Neuro-Behcet's syndrome: report of an autopsy case. Bull Osaka Med Sch 1964;10:105-119.
22 Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease. Curr Opin Rheumatol 2015;27:24-31.   DOI
23 Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behcet's disease. Inflamm Bowel Dis 2001;7:243-249.   DOI
24 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2017;32:769-777.   DOI
25 Maruyama Y, Hisamatsu T, Matsuoka K, et al. A case of intestinal Behcet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012;51:2125-2129.   DOI
26 Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis 2011;17:605-613.   DOI
27 Park J, Cheon JH. Could adalimumab be used safely and effectively in intestinal Behcet's disease refractory to conventional therapy? Intest Res 2017;15:263-265.   DOI
28 Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013;58:496-503.   DOI
29 Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012;18:750-757.   DOI
30 Park J, Cheon JH, Park YE, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behcet's disease. Int J Colorectal Dis 2017;32:745-751.   DOI
31 Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behcet's disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 2017;36:451-455.   DOI
32 Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 2015;13:940-948.e3.   DOI
33 Tanida S, Mizoshita T, Nishie H, et al. Long-term efficacy of adalimumab in patients with intestinal Behcet's disease: eight consecutive cases. J Clin Med Res 2016;8:334-337.   DOI
34 Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res 2017;15:395-401.   DOI
35 Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008;14:1259-1264.   DOI
36 Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol 2014;49:156-162.   DOI
37 Han M, Jung YS, Kim WH, Cheon JH, Park S. Incidence and clinical outcomes of intestinal Behcet's disease in Korea, 2011-2014: a nationwide population-based study. J Gastroenterol 2017;52:920-928.   DOI
38 Lopalco G, Rigante D, Venerito V, et al. Update on the medical management of gastrointestinal Behcet's disease. Mediators Inflamm 2017;2017:1460491.
39 Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behcet's disease. Intest Res 2017;15:318-327.   DOI
40 Goel N, Stephens S. Certolizumab pegol. MAbs 2010;2:137-147.   DOI
41 Nanke Y, Yago T, Kotake S. The role of Th17 cells in the pathogenesis of Behcet's disease. J Clin Med 2017;6:E74.   DOI
42 Smola MG, Soyer HP, Scharnagl E. Surgical treatment of dermatofibrosarcoma protuberans: a retrospective study of 20 cases with review of literature. Eur J Surg Oncol 1991;17:447-453.
43 Toyonaga T, Nakase H, Matsuura M, et al. Refractoriness of intestinal Behcet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies: our case experience and review of the literature. Digestion 2013;88:217-221.   DOI
44 Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999;42:1967-1974.   DOI
45 Gul A. Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(5 Suppl 24):S6-S12.
46 Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNFalpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 2002;11:87-93.   DOI
47 Emmi G, Silvestri E, Bella CD, et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-alpha in early phases of the disease. Medicine (Baltimore) 2016;95:e5516.   DOI
48 Kimura M, Tsuji Y, Iwai M, et al. Usefulness of adalimumab for treating a case of intestinal Behcet's disease with trisomy 8 myelodysplastic syndrome. Intest Res 2015;13:166-169.   DOI
49 Mizoshita T, Tanida S, Joh T. Adalimumab treatment in intestinal Behcet's disease: relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement. Dig Liver Dis 2015;47:991-992.   DOI
50 Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet's disease. Cell Biochem Biophys 2014;69:735-739.   DOI
51 Vitale A, Emmi G, Lopalco G, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behcet's disease. Clin Rheumatol 2017;36:2063-2069.   DOI
52 Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab pegol treatment in Behcet's disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol 2017;27:1031-1035.   DOI
53 van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007;66:565-566.
54 De Cassan C, De Vroey B, Dussault C, Hachulla E, Buche S, Colombel JF. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. J Crohns Colitis 2011;5:364-368.   DOI
55 Sugita S, Yamada Y, Horie S, et al. Induction of T regulatory cells by cytotoxic T-lymphocyte antigen-2alpha on corneal endothelial cells. Invest Ophthalmol Vis Sci 2011;52:2598-2605.   DOI
56 Kappen JH, Dik WA, Dingjan GM, et al. Cytokines in the colon of a patient with Behcet's disease. Arthritis Res Ther 2009;11:412.   DOI
57 Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine 2003;24:210-218.   DOI
58 Accardo-Palumbo A, Giardina AR, Ciccia F, et al. Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behcet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther 2010;12:R109.   DOI
59 Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther 2012;14:R99.   DOI
60 Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H. A young girl with refractory intestinal Behcet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int 2013;33:3105-3108.   DOI
61 Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001;120:995-999.   DOI
62 Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011;21:184-191.   DOI
63 Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013;19:1833-1838.
64 Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med 2013;52:1855-1862.   DOI
65 Iriarte A, Zaera C, Bachiller-Corral J, Lopez-Sanroman A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol 2017;40:117-121.   DOI
66 Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105.
67 Curigliano V, Giovinale M, Fonnesu C, et al. Efficacy of etanercept in the treatment of a patient with Behcet's disease. Clin Rheumatol 2008;27:933-936.   DOI
68 Mohammed RH. Etanercept therapy in Behcet's disease: the tight control strategy in refractory disease. Z Rheumatol 2014;73:650-656.   DOI
69 Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49:1694-1698.   DOI
70 Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-647.   DOI
71 Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008;10:393-406.
72 Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108:1835-1842.   DOI
73 Bewtra M. Lymphoma in inflammatory bowel disease and treatment decisions. Am J Gastroenterol 2012;107:964-970.   DOI